Literature DB >> 28799954

Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder.

Lauren B Burhans1, Carrie A Smith-Bell, Bernard G Schreurs.   

Abstract

Glutamatergic dysfunction is implicated in many neuropsychiatric conditions, including post-traumatic stress disorder (PTSD). Glutamate antagonists have shown some utility in treating PTSD symptoms, whereas glutamate agonists may facilitate cognitive behavioral therapy outcomes. We have developed an animal model of PTSD, based on conditioning of the rabbit's eyeblink response, that addresses two key features: conditioned responses (CRs) to cues associated with an aversive event and a form of conditioned hyperarousal referred to as conditioning-specific reflex modification (CRM). The optimal treatment to reduce both CRs and CRM is unpaired extinction. The goals of the study were to examine whether treatment with the N-methyl-D-aspartate glutamate receptor antagonist ketamine could reduce CRs and CRM, and whether the N-methyl-D-aspartate agonist D-cycloserine combined with unpaired extinction treatment could enhance the extinction of both. Administration of a single dose of subanesthetic ketamine had no significant immediate or delayed effect on CRs or CRM. Combining D-cycloserine with a single day of unpaired extinction facilitated extinction of CRs in the short term while having no impact on CRM. These results caution that treatments may improve one aspect of the PTSD symptomology while having no significant effects on other symptoms, stressing the importance of a multiple-treatment approach to PTSD and of animal models that address multiple symptoms.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28799954      PMCID: PMC5599342          DOI: 10.1097/FBP.0000000000000333

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  45 in total

1.  Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.

Authors:  Michael J Honsberger; Jane R Taylor; Philip R Corlett
Journal:  Schizophr Res       Date:  2015-02-24       Impact factor: 4.939

2.  Glutamatergic system abnormalities in posttraumatic stress disorder.

Authors:  Daisuke Nishi; Kenji Hashimoto; Hiroko Noguchi; Kei Hamazaki; Tomohito Hamazaki; Yutaka Matsuoka
Journal:  Psychopharmacology (Berl)       Date:  2015-08-22       Impact factor: 4.530

3.  Conditioning the unconditioned response: modification of the rabbit's (Oryctolagus cuniculus) unconditioned nictitating membrane response.

Authors:  B G Schreurs; T Shi; S Pineda; D L Buck
Journal:  J Exp Psychol Anim Behav Process       Date:  2000-04

4.  Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men.

Authors:  Najmeh Khalili-Mahani; Marieke Niesters; Matthias J van Osch; Melly Oitzl; Ilya Veer; Mark de Rooij; Joop van Gerven; Mark A van Buchem; Christian F Beckmann; Serge A R B Rombouts; Albert Dahan
Journal:  Neuroimage       Date:  2014-12-29       Impact factor: 6.556

5.  Age- and dose-dependent facilitation of associative eyeblink conditioning by D-cycloserine in rabbits.

Authors:  L T Thompson; J F Disterhoft
Journal:  Behav Neurosci       Date:  1997-12       Impact factor: 1.912

6.  Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine.

Authors:  Florian Duclot; Iara Perez-Taboada; Katherine N Wright; Mohamed Kabbaj
Journal:  Neuropharmacology       Date:  2016-06-22       Impact factor: 5.250

Review 7.  Induction and Expression of Fear Sensitization Caused by Acute Traumatic Stress.

Authors:  Jennifer N Perusini; Edward M Meyer; Virginia A Long; Vinuta Rau; Nathaniel Nocera; Jacob Avershal; James Maksymetz; Igor Spigelman; Michael S Fanselow
Journal:  Neuropsychopharmacology       Date:  2015-08-06       Impact factor: 7.853

8.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

9.  D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.

Authors:  Jasper A J Smits; David Rosenfield; Michael W Otto; Luana Marques; Michelle L Davis; Alicia E Meuret; Naomi M Simon; Mark H Pollack; Stefan G Hofmann
Journal:  J Psychiatr Res       Date:  2013-07-16       Impact factor: 4.791

10.  Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.

Authors:  E Engin; D Treit; C T Dickson
Journal:  Neuroscience       Date:  2009-03-24       Impact factor: 3.590

View more
  3 in total

1.  Propranolol produces short-term facilitation of extinction in a rabbit model of post-traumatic stress disorder.

Authors:  Lauren B Burhans; Carrie A Smith-Bell; Bernard G Schreurs
Journal:  Neuropharmacology       Date:  2018-03-23       Impact factor: 5.250

2.  Inactivation of the interpositus nucleus blocks the acquisition of conditioned responses and timing changes in conditioning-specific reflex modification of the rabbit eyeblink response.

Authors:  Lauren B Burhans; Bernard G Schreurs
Journal:  Neurobiol Learn Mem       Date:  2018-07-24       Impact factor: 2.877

3.  Inactivation of the interpositus nucleus during unpaired extinction does not prevent extinction of conditioned eyeblink responses or conditioning-specific reflex modification.

Authors:  Lauren B Burhans; Bernard G Schreurs
Journal:  Behav Neurosci       Date:  2019-03-14       Impact factor: 1.912

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.